nach oben

Pituitary

Erschienen in:

01.09.2007

Mechanism of action of octreotide in acromegalic tumours in vivo using dynamic contrast-enhanced magnetic resonance imaging

verfasst von: Thozhukat Sathyapalan, Martin Lowry, Lindsay W Turnbull, Chris Rowland-Hill, Stephen L Atkin

Erschienen in: Pituitary | Ausgabe 3/2007

Einloggen, um Zugang zu erhalten

Abstract

Context

Octreotide causes significant tumour shrinkage in patients with acromegaly but the exact mechanism of action is unclear in vivo.

Objective

To determine the mechanism of action of octreotide in vivo using dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI).

Design

Five patients with acromegaly were treated with octreotide as primary medical therapy. DCE-MRI was done at baseline and 24 weeks. Local ethical committee approval was granted.

Setting

Study was done in a tertiary care centre.

Patients

Five patients with newly diagnosed acromegaly were recruited.

Intervention

Patients were started on subcutaneous octreotide and DCE-MRI was done on 0 and 24 weeks.

Main outcome measures

Amplitude of contrast intake, exchange rate and maximum enhancement index of tumour tissue was compared before and after treatment.

Results

Amplitude of contrast intake (9.87 ± 3.52 vs. 4.97 ± 1.96 P ≤ 0.05) and exchange rate (6.27 ± 1.57 vs. 1.63 ± 0.76 P value ≤ 0.01) were significantly higher at baseline in adenoma compared to normal pituitary tissue but was comparable to normal pituitary tissue after treatment. There was a significant decrease in amplitude of contrast intake and exchange rate which relates to functional vascularity of adenoma at 24 weeks compared to baseline (P-values 0.026 and 0.002 respectively) but there were no significant changes in the normal pituitary tissue.

Conclusion

DCE-MRI in acromegalic tumours treated with octreotide showed a significant reduction in functional vascularity after octreotide therapy compared to baseline in pituitary adenomas. This supports the antiangiogenic action of somatostatin analogue therapy in vitro, but it remains unclear if this mechanism is important clinically in analogue pre-treatment reducing the effect of radiotherapy on these pituitary tumours.

Bevan JS (2005) Clinical review: the antitumoral effects of somatostatin analog therapy in acromegaly. J Clin Endocrinol Metab 90:1856–1863PubMedCrossRef

Bevan JS, Atkin SL, Atkinson AB et al. (2002) Primary medical therapy for acromegaly: an open, prospective, multicenter study of the effects of subcutaneous and intramuscular slow-release octreotide on growth hormone, insulin-like growth factor-I, and tumor size. J Clin Endocrinol Metab 87:4554–4563PubMedCrossRef

Ferjoux G, Bousquet C, Cordelier P et al. (2000) Signal transduction of somatostatin receptors negatively controlling cell proliferation. J Physiol Paris 94:205–210PubMedCrossRef

Lamberts SW, Reubi JC, Krenning EP (1994) The role of somatostatin analogs in the control of tumor growth. Semin Oncol 21:61–64PubMed

Buscail L, Esteve JP, Saint-Laurent N et al. (1995) Inhibition of cell proliferation by the somatostatin analogue RC-160 is mediated by somatostatin receptor subtypes SSTR2 and SSTR5 through different mechanisms. Proc Natl Acad Sci USA 92:1580–1584PubMedCrossRef

Losa M, Ciccarelli E, Mortini P et al. (2001) Effects of octreotide treatment on the proliferation and apoptotic index of GH-secreting pituitary adenomas. J Clin Endocrinol Metab 86:5194–5200PubMedCrossRef

Garcia de la Torre N, Wass JA, Turner HE (2002) Antiangiogenic effects of somatostatin analogues. Clin Endocrinol (Oxf) 57:425–441CrossRef

Dasgupta P (2004) Somatostatin analogues: multiple roles in cellular proliferation, neoplasia, and angiogenesis. Pharmacol Ther 102:61–85PubMedCrossRef

Adams RL, Adams IP, Lindow SW, Zhong W, Atkin SL (2005) Somatostatin receptors 2 and 5 are preferentially expressed in proliferating endothelium. Br J Cancer 92:1493–1498PubMedCrossRef

10.

Mross K, Fuxius S, Drevs J (2002) Serial measurements of pharmacokinetics, DCE-MRI, blood flow, PET and biomarkers in serum/plasma—what is a useful tool in clinical studies of anti-angiogenic drugs? Int J Clin Pharmacol Ther 40:573–574PubMed

11.

Tofts PS, Kermode AG (1991) Measurement of the blood-brain barrier permeability and leakage space using dynamic MR imaging. 1 Fundamental concepts. Magn Reson Med 17:357–367PubMedCrossRef

12.

Zirrgiebel U, Drevs J (2003) Surrogate marker in clinical studies with anti-angiogenic drugs. Int J Clin Pharmacol Ther 41:600–602PubMed

13.

Tofts PS (1996) Optimal detection of blood-brain barrier defects with Gd-DTPA MRI-the influences of delayed imaging and optimised repetition time. Magn Reson Imaging 14:373–380PubMedCrossRef

14.

Brix G, Semmler W, Port R, Schad LR, Layer G, Lorenz WJ (1991) Pharmacokinetic parameters in CNS Gd-DTPA enhanced MR imaging. J Comput Assist Tomogr 15:621–628PubMedCrossRef

15.

Larsson HB, Tofts PS (1992) Measurement of blood-brain barrier permeability using dynamic Gd-DTPA scanning—a comparison of methods. Magn Reson Med 24:174–176PubMedCrossRef

16.

Landolt AM, Haller D, Lomax N et al (2000) Octreotide may act as a radioprotective agent in acromegaly. J Clin Endocrinol Metab 85:1287–1289PubMedCrossRef

17.

Pollock BE, Nippoldt TB, Stafford SL, Foote RL, Abboud CF (2002) Results of stereotactic radiosurgery in patients with hormone-producing pituitary adenomas: factors associated with endocrine normalization. J Neurosurg 97:525–530PubMedCrossRef

18.

Cozzi R, Barausse M, Asnaghi D, Dallabonzana D, Lodrini S, Attanasio R (2001) Failure of radiotherapy in acromegaly. Eur J Endocrinol 145:717–726PubMedCrossRef

19.

Mao XW (2006) A quantitative study of the effects of ionizing radiation on endothelial cells and capillary-like network formation. Technol Cancer Res Treat 5:127–134PubMed

20.

Castinetti F, Taieb D, Kuhn JM et al (2005) Outcome of gamma knife radiosurgery in 82 patients with acromegaly: correlation with initial hypersecretion. J Clin Endocrinol Metab 90:4483–4488PubMedCrossRef

21.

Attanasio R, Epaminonda P, Motti E et al (2003) Gamma-knife radiosurgery in acromegaly: a 4-year follow-up study. J Clin Endocrinol Metab 88:3105–3112PubMedCrossRef

Titel: Mechanism of action of octreotide in acromegalic tumours in vivo using dynamic contrast-enhanced magnetic resonance imaging
verfasst von: Thozhukat Sathyapalan
Martin Lowry
Lindsay W Turnbull
Chris Rowland-Hill
Stephen L Atkin
Publikationsdatum: 01.09.2007
Verlag: Springer US
Erschienen in: Pituitary / Ausgabe 3/2007
Print ISSN: 1386-341X
Elektronische ISSN: 1573-7403
DOI: https://doi.org/10.1007/s11102-007-0044-8

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Context

Objective

Design

Setting

Patients

Intervention

Main outcome measures

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2007

Analysis of GNAS mutations in 60 growth hormone secreting pituitary tumors: correlation with clinical and pathological characteristics and surgical outcome based on highly sensitive GH and IGF-I criteria for remission

Long-term effects of the combination of pegvisomant with somatostatin analogs (SSA) on glucose homeostasis in non-diabetic patients with active acromegaly partially resistant to SSA

TSH-secreting pituitary adenomas: follow-up of 11 cases and review of the literature

Optic atrophy due to Curvularia lunata mucocoele

Pituitary tumor enlargement in two patients with acromegaly during pegvisomant therapy

Effect of dopamine agonists on prolactinomas and normal pituitary assessed by dynamic contrast enhanced magnetic resonance imaging (DCE-MRI)